Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 176 entries
Sorted by: Best Match Show Resources per page
Preface. Novel targets and drugs to prevent atherogenesis and its consequences.

European journal of pharmacology

Riksen NP, Rongen GA.
PMID: 26370897
Eur J Pharmacol. 2015 Sep 15;763:1-2. doi: 10.1016/j.ejphar.2015.08.042.

No abstract available.

Cite
Riksen NP, Rongen GA. Preface. Novel targets and drugs to prevent atherogenesis and its consequences. Eur J Pharmacol. 2015;763:1-2doi: 10.1016/j.ejphar.2015.08.042.
Riksen, N. P., & Rongen, G. A. (2015). Preface. Novel targets and drugs to prevent atherogenesis and its consequences. European journal of pharmacology, 7631-2. https://doi.org/10.1016/j.ejphar.2015.08.042
Riksen, Niels P, and Rongen, Gerard A. "Preface. Novel targets and drugs to prevent atherogenesis and its consequences." European journal of pharmacology vol. 763 (2015): 1-2. doi: https://doi.org/10.1016/j.ejphar.2015.08.042
Riksen NP, Rongen GA. Preface. Novel targets and drugs to prevent atherogenesis and its consequences. Eur J Pharmacol. 2015 Sep 15;763:1-2. doi: 10.1016/j.ejphar.2015.08.042. PMID: 26370897.
Copy Download .nbib Format: NLM
Preparing pathology for precision medicine: challenges and opportunities.

Virchows Archiv : an international journal of pathology

Kaul KL.
PMID: 28512674
Virchows Arch. 2017 Aug;471(2):141-146. doi: 10.1007/s00428-017-2141-z. Epub 2017 May 16.

No abstract available.

Cite
Kaul KL. Preparing pathology for precision medicine: challenges and opportunities. Virchows Arch. 2017;471(2):141-146doi: 10.1007/s00428-017-2141-z.
Kaul, K. L. (2017). Preparing pathology for precision medicine: challenges and opportunities. Virchows Archiv : an international journal of pathology, 471(2), 141-146. https://doi.org/10.1007/s00428-017-2141-z
Kaul, Karen L. "Preparing pathology for precision medicine: challenges and opportunities." Virchows Archiv : an international journal of pathology vol. 471,2 (2017): 141-146. doi: https://doi.org/10.1007/s00428-017-2141-z
Kaul KL. Preparing pathology for precision medicine: challenges and opportunities. Virchows Arch. 2017 Aug;471(2):141-146. doi: 10.1007/s00428-017-2141-z. Epub 2017 May 16. PMID: 28512674.
Copy Download .nbib Format: NLM
Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options.

British journal of haematology

Brisse E, Matthys P, Wouters CH.
PMID: 27292929
Br J Haematol. 2016 Jul;174(2):175-87. doi: 10.1111/bjh.14144. Epub 2016 Jun 12.

The cytokine storm syndrome 'haemophagocytic lymphohistiocytosis' (HLH) is an under-recognized hyperinflammatory disorder, causing high morbidity and mortality risk in children and adults. It can be subdivided into a primary, genetic form and a secondary, acquired form that complicates diverse...

Cite
Brisse E, Matthys P, Wouters CH. Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options. Br J Haematol. 2016;174(2):175-87doi: 10.1111/bjh.14144.
Brisse, E., Matthys, P., & Wouters, C. H. (2016). Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options. British journal of haematology, 174(2), 175-87. https://doi.org/10.1111/bjh.14144
Brisse, Ellen, et al. "Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options." British journal of haematology vol. 174,2 (2016): 175-87. doi: https://doi.org/10.1111/bjh.14144
Brisse E, Matthys P, Wouters CH. Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options. Br J Haematol. 2016 Jul;174(2):175-87. doi: 10.1111/bjh.14144. Epub 2016 Jun 12. PMID: 27292929.
Copy Download .nbib Format: NLM
Cystic fibrosis: a model for personalized genetic medicine.

North Carolina medical journal

Green DM.
PMID: 24316771
N C Med J. 2013 Nov-Dec;74(6):486-7.

No abstract available.

Cite
Green DM. Cystic fibrosis: a model for personalized genetic medicine. N C Med J. 2013;74(6):486-7
Green, D. M. (2013). Cystic fibrosis: a model for personalized genetic medicine. North Carolina medical journal, 74(6), 486-7.
Green, Deanna M. "Cystic fibrosis: a model for personalized genetic medicine." North Carolina medical journal vol. 74,6 (2013): 486-7.
Green DM. Cystic fibrosis: a model for personalized genetic medicine. N C Med J. 2013 Nov-Dec;74(6):486-7. PMID: 24316771.
Copy Download .nbib Format: NLM
The new therapeutical scenario of Hodgkin lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology

Stathis A, Younes A.
PMID: 26037796
Ann Oncol. 2015 Oct;26(10):2026-33. doi: 10.1093/annonc/mdv256. Epub 2015 Jun 02.

Hodgkin lymphoma (HL) remains one of the most curable human cancers, as modern combination chemotherapy and radiation therapy cure ∼ 80% of patients. Over the last two decades, the major efforts were focused on the development of more intensive...

Cite
Stathis A, Younes A. The new therapeutical scenario of Hodgkin lymphoma. Ann Oncol. 2015;26(10):2026-33doi: 10.1093/annonc/mdv256.
Stathis, A., & Younes, A. (2015). The new therapeutical scenario of Hodgkin lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 26(10), 2026-33. https://doi.org/10.1093/annonc/mdv256
Stathis, A, and Younes, A. "The new therapeutical scenario of Hodgkin lymphoma." Annals of oncology : official journal of the European Society for Medical Oncology vol. 26,10 (2015): 2026-33. doi: https://doi.org/10.1093/annonc/mdv256
Stathis A, Younes A. The new therapeutical scenario of Hodgkin lymphoma. Ann Oncol. 2015 Oct;26(10):2026-33. doi: 10.1093/annonc/mdv256. Epub 2015 Jun 02. PMID: 26037796.
Copy Download .nbib Format: NLM
[Pharmacoeconomics of molecular targeting drugs].

Nihon rinsho. Japanese journal of clinical medicine

Igarashi A.
PMID: 25016820
Nihon Rinsho. 2014 Jun;72(6):1157-62.

No abstract available.

Cite
Igarashi A. [Pharmacoeconomics of molecular targeting drugs]. Nihon Rinsho. 2014;72(6):1157-62
Igarashi, A. (2014). [Pharmacoeconomics of molecular targeting drugs]. Nihon rinsho. Japanese journal of clinical medicine, 72(6), 1157-62.
Igarashi, Ataru. "[Pharmacoeconomics of molecular targeting drugs]." Nihon rinsho. Japanese journal of clinical medicine vol. 72,6 (2014): 1157-62.
Igarashi A. [Pharmacoeconomics of molecular targeting drugs]. Nihon Rinsho. 2014 Jun;72(6):1157-62. Japanese. PMID: 25016820.
Copy Download .nbib Format: NLM
Interleukin-17 in atherosclerosis: Still a long road ahead.

International journal of cardiology

Ladeiras-Lopes R, Koenig W.
PMID: 26478522
Int J Cardiol. 2016 Jan 01;202:932. doi: 10.1016/j.ijcard.2015.10.060. Epub 2015 Oct 09.

No abstract available.

Cite
Ladeiras-Lopes R, Koenig W. Interleukin-17 in atherosclerosis: Still a long road ahead. Int J Cardiol. 2015;202:932doi: 10.1016/j.ijcard.2015.10.060.
Ladeiras-Lopes, R., & Koenig, W. (2016). Interleukin-17 in atherosclerosis: Still a long road ahead. International journal of cardiology, 202932. https://doi.org/10.1016/j.ijcard.2015.10.060
Ladeiras-Lopes, Ricardo, and Koenig, Wolfgang. "Interleukin-17 in atherosclerosis: Still a long road ahead." International journal of cardiology vol. 202 (2016): 932. doi: https://doi.org/10.1016/j.ijcard.2015.10.060
Ladeiras-Lopes R, Koenig W. Interleukin-17 in atherosclerosis: Still a long road ahead. Int J Cardiol. 2016 Jan 01;202:932. doi: 10.1016/j.ijcard.2015.10.060. Epub 2015 Oct 09. PMID: 26478522.
Copy Download .nbib Format: NLM
[Current status and challenges from therapeutic targeting of microRNAs].

Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases

Ji X, Wu B, Ni C.
PMID: 26887281
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2015 Nov;33(11):869-73.

No abstract available.

Cite
Ji X, Wu B, Ni C. [Current status and challenges from therapeutic targeting of microRNAs]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2015;33(11):869-73
Ji, X., Wu, B., & Ni, C. (2015). [Current status and challenges from therapeutic targeting of microRNAs]. Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases, 33(11), 869-73.
Ji, Xiaoming, et al. "[Current status and challenges from therapeutic targeting of microRNAs]." Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases vol. 33,11 (2015): 869-73.
Ji X, Wu B, Ni C. [Current status and challenges from therapeutic targeting of microRNAs]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2015 Nov;33(11):869-73. Chinese. PMID: 26887281.
Copy Download .nbib Format: NLM
DISCOVERY OF MOLECULARLY TARGETED THERAPIES.

Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing

Regan K, Abrams Z, Sharpnack M, Srivastava A, Huang K, Shah N, Payne PR.
PMID: 26776168
Pac Symp Biocomput. 2016;21:1-8.

No abstract available.

Cite
Regan K, Abrams Z, Sharpnack M, et al. DISCOVERY OF MOLECULARLY TARGETED THERAPIES. Pac Symp Biocomput. 2016;21:1-8
Regan, K., Abrams, Z., Sharpnack, M., Srivastava, A., Huang, K., Shah, N., & Payne, P. R. (2016). DISCOVERY OF MOLECULARLY TARGETED THERAPIES. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 211-8.
Regan, Kelly, et al. "DISCOVERY OF MOLECULARLY TARGETED THERAPIES." Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing vol. 21 (2016): 1-8.
Regan K, Abrams Z, Sharpnack M, Srivastava A, Huang K, Shah N, Payne PR. DISCOVERY OF MOLECULARLY TARGETED THERAPIES. Pac Symp Biocomput. 2016;21:1-8. PMID: 26776168; PMCID: PMC4874173.
Copy Download .nbib Format: NLM
Atherosclerosis: Recent trials, new targets and future directions.

International journal of cardiology

Ladeiras-Lopes R, Agewall S, Tawakol A, Staels B, Stein E, Mentz RJ, Leite-Moreira A, Zannad F, Koenig W.
PMID: 26002254
Int J Cardiol. 2015 Aug 01;192:72-81. doi: 10.1016/j.ijcard.2015.05.013. Epub 2015 May 08.

Mortality from cardiovascular diseases (CVD) represents the primary cause of death worldwide. Prevention or treatment of atherosclerosis and its clinical sequelae is a central goal in the management of patients with established vascular disease or those at high-risk for...

Cite
Ladeiras-Lopes R, Agewall S, Tawakol A, et al. Atherosclerosis: Recent trials, new targets and future directions. Int J Cardiol. 2015;192:72-81doi: 10.1016/j.ijcard.2015.05.013.
Ladeiras-Lopes, R., Agewall, S., Tawakol, A., Staels, B., Stein, E., Mentz, R. J., Leite-Moreira, A., Zannad, F., & Koenig, W. (2015). Atherosclerosis: Recent trials, new targets and future directions. International journal of cardiology, 19272-81. https://doi.org/10.1016/j.ijcard.2015.05.013
Ladeiras-Lopes, Ricardo, et al. "Atherosclerosis: Recent trials, new targets and future directions." International journal of cardiology vol. 192 (2015): 72-81. doi: https://doi.org/10.1016/j.ijcard.2015.05.013
Ladeiras-Lopes R, Agewall S, Tawakol A, Staels B, Stein E, Mentz RJ, Leite-Moreira A, Zannad F, Koenig W. Atherosclerosis: Recent trials, new targets and future directions. Int J Cardiol. 2015 Aug 01;192:72-81. doi: 10.1016/j.ijcard.2015.05.013. Epub 2015 May 08. PMID: 26002254.
Copy Download .nbib Format: NLM
Commentary: Implications of cancer managed as a "chronic illness".

Current oncology reports

Markman M.
PMID: 21221861
Curr Oncol Rep. 2011 Apr;13(2):90-1. doi: 10.1007/s11912-010-0148-6.

In an increasing number of settings it is appropriate to consider cancer as a very serious but also a chronic disease process. This commentary discusses a number of highly clinically relevant implications of this important evolution in the management...

Cite
Markman M. Commentary: Implications of cancer managed as a "chronic illness". Curr Oncol Rep. 2011;13(2):90-1doi: 10.1007/s11912-010-0148-6.
Markman, M. (2011). Commentary: Implications of cancer managed as a "chronic illness". Current oncology reports, 13(2), 90-1. https://doi.org/10.1007/s11912-010-0148-6
Markman, Maurie. "Commentary: Implications of cancer managed as a "chronic illness"." Current oncology reports vol. 13,2 (2011): 90-1. doi: https://doi.org/10.1007/s11912-010-0148-6
Markman M. Commentary: Implications of cancer managed as a "chronic illness". Curr Oncol Rep. 2011 Apr;13(2):90-1. doi: 10.1007/s11912-010-0148-6. PMID: 21221861.
Copy Download .nbib Format: NLM
Whether it is personalized, precision, or mechanistic medicine--- the clinical laboratory has a role.

Clinical biochemistry

Kavsak PA.
PMID: 22424084
Clin Biochem. 2012 Apr;45(6):384. doi: 10.1016/j.clinbiochem.2012.03.002.

No abstract available.

Cite
Kavsak PA. Whether it is personalized, precision, or mechanistic medicine--- the clinical laboratory has a role. Clin Biochem. 2012;45(6):384doi: 10.1016/j.clinbiochem.2012.03.002.
Kavsak, P. A. (2012). Whether it is personalized, precision, or mechanistic medicine--- the clinical laboratory has a role. Clinical biochemistry, 45(6), 384. https://doi.org/10.1016/j.clinbiochem.2012.03.002
Kavsak, Peter A. "Whether it is personalized, precision, or mechanistic medicine--- the clinical laboratory has a role." Clinical biochemistry vol. 45,6 (2012): 384. doi: https://doi.org/10.1016/j.clinbiochem.2012.03.002
Kavsak PA. Whether it is personalized, precision, or mechanistic medicine--- the clinical laboratory has a role. Clin Biochem. 2012 Apr;45(6):384. doi: 10.1016/j.clinbiochem.2012.03.002. PMID: 22424084.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 176 entries